Dificlir

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

fidaxomicin

Available from:

Tillotts Pharma GmbH

ATC code:

A07AA12

INN (International Name):

fidaxomicin

Therapeutic group:

Antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti

Therapeutic area:

Infezzjonijiet ta 'Clostridium

Therapeutic indications:

Dificlir pilloli miksija b'rita huwa indikat għall-kura ta Clostridioides difficile infezzjonijiet (CDI) magħruf ukoll bħala C. difficile-assoċjat dijarea (CDAD) f'pazjenti adulti u pedjatriċi b'piż tal-ġisem ta ' mill-inqas 12-il. 5 kg. Konsiderazzjoni għandha tingħata sabiex il-linji gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi. Dificlir granijiet għal suspensjoni orali huwa indikat għall-kura ta Clostridioides difficile infezzjonijiet (CDI) magħruf ukoll bħala C. difficile-assoċjat dijarea (CDAD) fl-adulti u f'pazjenti pedjatriċi mit-twelid sa < 18-il sena. Konsiderazzjoni għandha tingħata sabiex il-linji gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Product summary:

Revision: 17

Authorization status:

Awtorizzat

Authorization date:

2011-12-05

Patient Information leaflet

                                33
B. FULJETT TA’ TAGĦRIF
34
FULJETT TA’ TAGĦRIF:INFORMAZZJONI GĦALL-UTENT
DIFICLIR 200 MG PILLOLI MIKSIJA B’RITA
fidaxomicin
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
−
Żomm dan il-fuljett.Jista’ jkollok bżonn terġa’ taqrah.
−
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
−
Din il-mediċina ġiet mogħtija lilek biss.M’għandekx tgħaddiha
lil persuni oħra.Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
−
Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-ispiżjar
tiegħek.Dan jinkludi xi effett
sekondarju possibbli li m’huwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu DIFICLIR u gћalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu DIFICLIR
3.
Kif għandek tieħu DIFICLIR
4.
Effetti sekondarji possibbli
5.
Kif taħżen DIFICLIR
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU DIFICLIR U GЋALXIEX JINTUŻA
DIFICLIR huwa antibijotiku li fih is-sustanza attiva fidaxomicin.
DIFICLIR pilloli miksija b’rita jintużaw fl-adulti, fl-adolexxenti
u fit-tfal b’piż tal-ġisem ta’ mill-inqas
12.5 kg biex jiġu kkurati infezzjonijiet tal-membrana tal-kolon
(il-musrana l-kbira) b’ċerti batterji
magħrufa bħala
_Clostridioides difficile_
. Din il-marda serja tista’ tirriżulta f’dijarea qawwija u li
tikkawża wġigħ.
DIFICLIR jaħdem billi joqtol il-batterji li jikkawżaw l-infezzjoni u
jgħin biex inaqqas id-dijarea
assoċjata.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU DIFICLIR
TIĦUX DIFICLIR
−
Jekk inti allerġiku għall-fidaxomicin jew għal xi sustanza oħra
ta’ din il-mediċina (elenkati
f’sezzjoni 6).
TWISSIJIET U PREKAWZJONIJIET
Kellem lit-tabib jew l-ispiżjar tiegħek qabel tieħu DIFICLIR:
Jekk inti tħoss li jista’ jkollok reazzjoni allerġika severa bħal
problemi tan-nifs (dispneja), nefħa tal-
wiċċ jew tal-gerżuma (anġjodema), raxx sever, ħakk se
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
_ _
2
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
DIFICLIR 200 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pillola miksija b’rita fiha 200 mg ta’ fidaxomicin.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita.
Pilloli forma ta’ kapsula ta’ 14 mm, ta’ kulur abjad jew abjad
jagħti fil-griż, imnaqqxa bl-ittri “FDX”
fuq naħa u bin-numru “200” fuq in-naħa l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
DIFICLIR pilloli miksija b’rita hu indikat għall-kura ta’
infezzjonijiet minn
_Clostridioides difficile_
(CDI), magħrufa wkoll bħala dijarea marbuta mal-infezzjoni
_C. difficile _
(CDAD) f’pazjenti adulti u
pedjatriċi b’piż tal-ġisem ta’ mill-inqas 12.5 kg (ara
sezzjonijiet 4.2 u 5.1).
Konsiderazzjoni għandha tingħata għal linji gwida uffiċjali dwar
l-użu xieraq ta’ sustanzi antibatteriċi.
4.2
POŻOLOĠIJAU METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
_ _
_Adulti _
Dożaġġ standard
Id-doża rakkomandata hija 200 mg (pillola waħda) li tingħata
darbtejn kuljum (darba kull 12-il siegħa)
għal 10 ijiem (ara sezzjoni 5.1).
Granuli DIFICLIR 40 mg / ml għal sospensjoni orali jistgħu jintużaw
f'pazjenti adulti b'diffikultà biex
tibla 'l-pilloli.
Dożaġġ pulzat estiż
Fidaxomicin 200 mg pilloli jingħataw darbtejn kuljum għall-jiem 1-5
(l-ebda teħid ta’ pillola f’jum 6)
imbagħad darba kuljum f’jiem alternati għall-jiem 7-25 (ara
sezzjoni 5.1).
Jekk tkun intesiet doża, id-doża maqbuża għandha tittieħed malajr
kemm jista’ jkun jew, jekk ikun
kważi sar il-ħin għad-doża li jmiss, il-pillola għandha tinqabeż
għal kollox.
Popolazzjoni speċjali
_Popolazzjoni anzjana _
L-ebda aġġustament tad-doża mhu kkunsidrat li hu neċessarju (ara
sezzjoni 5.2).
_ _
_Indeboliment tal-kliewi _
3
L-ebda aġġustament tad-doża mhu kkunsidrat li hu neċessarju.
Minħabba d-
_data_
klinika limitata dwar
din il-popolazzjoni, 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-12-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-12-2022
Public Assessment Report Public Assessment Report Bulgarian 11-03-2020
Patient Information leaflet Patient Information leaflet Spanish 22-12-2022
Public Assessment Report Public Assessment Report Spanish 11-03-2020
Patient Information leaflet Patient Information leaflet Czech 22-12-2022
Public Assessment Report Public Assessment Report Czech 11-03-2020
Patient Information leaflet Patient Information leaflet Danish 22-12-2022
Public Assessment Report Public Assessment Report Danish 11-03-2020
Patient Information leaflet Patient Information leaflet German 22-12-2022
Public Assessment Report Public Assessment Report German 11-03-2020
Patient Information leaflet Patient Information leaflet Estonian 22-12-2022
Public Assessment Report Public Assessment Report Estonian 11-03-2020
Patient Information leaflet Patient Information leaflet Greek 22-12-2022
Public Assessment Report Public Assessment Report Greek 11-03-2020
Patient Information leaflet Patient Information leaflet English 22-12-2022
Public Assessment Report Public Assessment Report English 11-03-2020
Patient Information leaflet Patient Information leaflet French 22-12-2022
Public Assessment Report Public Assessment Report French 11-03-2020
Patient Information leaflet Patient Information leaflet Italian 22-12-2022
Public Assessment Report Public Assessment Report Italian 11-03-2020
Patient Information leaflet Patient Information leaflet Latvian 22-12-2022
Public Assessment Report Public Assessment Report Latvian 11-03-2020
Patient Information leaflet Patient Information leaflet Lithuanian 22-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-12-2022
Public Assessment Report Public Assessment Report Lithuanian 11-03-2020
Patient Information leaflet Patient Information leaflet Hungarian 22-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 22-12-2022
Public Assessment Report Public Assessment Report Hungarian 11-03-2020
Patient Information leaflet Patient Information leaflet Dutch 22-12-2022
Public Assessment Report Public Assessment Report Dutch 11-03-2020
Patient Information leaflet Patient Information leaflet Polish 22-12-2022
Public Assessment Report Public Assessment Report Polish 11-03-2020
Patient Information leaflet Patient Information leaflet Portuguese 22-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 22-12-2022
Public Assessment Report Public Assessment Report Portuguese 11-03-2020
Patient Information leaflet Patient Information leaflet Romanian 22-12-2022
Public Assessment Report Public Assessment Report Romanian 11-03-2020
Patient Information leaflet Patient Information leaflet Slovak 22-12-2022
Public Assessment Report Public Assessment Report Slovak 11-03-2020
Patient Information leaflet Patient Information leaflet Slovenian 22-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 22-12-2022
Public Assessment Report Public Assessment Report Slovenian 11-03-2020
Patient Information leaflet Patient Information leaflet Finnish 22-12-2022
Public Assessment Report Public Assessment Report Finnish 11-03-2020
Patient Information leaflet Patient Information leaflet Swedish 22-12-2022
Public Assessment Report Public Assessment Report Swedish 11-03-2020
Patient Information leaflet Patient Information leaflet Norwegian 22-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 22-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 22-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 22-12-2022
Patient Information leaflet Patient Information leaflet Croatian 22-12-2022
Public Assessment Report Public Assessment Report Croatian 11-03-2020

Search alerts related to this product

View documents history